William Maclaughlin
Hematology & Oncology · Chesapeake, VANPI 1164487419
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,984 of the $2,345 with a category attached, or 84.6%. It is spread thinly across 36 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,150 and has fallen 97.3% since, to $32 in 2024.
Across 111 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$330
- Taiho Oncology, Inc.$185
- Johnson & Johnson$182
- AstraZeneca$167
- GSK$160
- Genentech USA, Inc.$158
- plus $1K from 30 others
Across 54 payments — averaging $4923.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$76K
- E.r. Squibb & Sons, L.L.C.$40K
- Merck$35K
- Pfizer$35K
- Bristol Myers Squibb$25K
- Seagen Inc.$17K
- plus $38K from 4 others
What the payments were for
- Consulting fees$1607%
- Speaking & faculty fees$1506%
- Food & beverage$1,98485%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $330 |
| Taiho Oncology, Inc. | 4 | $185 |
| Johnson & Johnson(2 entities) | 13 | $182 |
| AstraZeneca | 8 | $167 |
| GSK | 1 | $160 |
| Genentech USA, Inc. | 9 | $158 |
| Novartis | 8 | $143 |
| Seagen Inc. | 6 | $113 |
| Amgen | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 6 | $96 |
| Pfizer | 5 | $85 |
| Incyte Corporation | 4 | $66 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Bristol Myers Squibb | 3 | $57 |
| Foundation Medicine, Inc. | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Coherus Oncology, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Lilly USA, LLC | 2 | $24 |
| Spectrum Pharmaceuticals Inc. | 1 | $24 |
| Partner Therapeutics, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Merck | 1 | $18 |
| AbbVie | 1 | $18 |
| Bayer | 1 | $18 |
| Acceleron Pharma, Inc. | 1 | $17 |
| Verastem, Inc. | 1 | $16 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| CSL Behring | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Mylan Institutional Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,345 in reported general payments places this provider in the 60th percentile of 293 hematology & oncology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $6,24611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Chesapeake
- Christian AgbisitChesapeake$6K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.